AI deals in the medical industry dropped in H1 2022

In the first half of 2022, the number of deals relating to artificial intelligence (AI) decreased significantly by 41.7% compared with the same period in 2021.

This marks a deceleration in growth from the 33.3% decrease in deals that occurred in H2 2021 relative to the same period a year earlier.

GlobalData’s deals database looks at mergers, acquisitions and venture capital and private equity investments taking place daily between thousands of companies across the world.

During first half of 2022, deals relating to AI accounted for 4.2% of all deals taking place in the sector. This represents a decrease from the figure of 4.8% in the first half of 2021.

GlobalData's thematic approach to sector activity seeks to group key company information on investments to see which industries are best placed to deal with any issues they may encounter.

These themes, of which AI is one, are best thought of as "any issue that keeps a CEO awake at night", and by tracking them, it becomes possible to ascertain which companies are leading the way on specific issues and which ones have some work to do.